Shanghai Haohai Biological Technology (SHA:688366, HKG:6826) obtained medical device registration from China's medical products administrator for its multifocal aspheric intraocular lens product.
The product is intended for vision correction in aphakic eyes of cataract patients, according to a Wednesday filing with the Shanghai bourse.
The registration is valid until March 2031.
Shares of the ophthalmic products manufacturer rose 3% on the Shanghai bourse and 2% on the Hong Kong bourse.